These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33997101)

  • 1. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs.
    Drago D; Foss-Campbell B; Wonnacott K; Barrett D; Ndu A
    Mol Ther Methods Clin Dev; 2021 Jun; 21():524-529. PubMed ID: 33997101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
    Rivera VM
    Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: international regulatory considerations on development pathways for cell therapies.
    Feigal EG; Tsokas K; Viswanathan S; Zhang J; Priest C; Pearce J; Mount N
    Stem Cells Transl Med; 2014 Aug; 3(8):879-87. PubMed ID: 25038248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future.
    Pimenta C; Bettiol V; Alencar-Silva T; Franco OL; Pogue R; Carvalho JL; Felipe MSS
    Clin Ther; 2021 May; 43(5):e103-e138. PubMed ID: 33892966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
    Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
    AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regenerative Medicine Therapies for Rare Diseases.
    Lapteva L; Vatsan R; Purohit-Sheth T
    Transl Sci Rare Dis; 2018 Dec; 3(3-4):121-132. PubMed ID: 30613470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
    Mahalatchimy A
    Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell therapy clinical research: A regulatory conundrum for academia.
    Nagpal A; Juttner C; Hamilton-Bruce MA; Rolan P; Koblar SA
    Adv Drug Deliv Rev; 2017 Dec; 122():105-114. PubMed ID: 27760370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registration pathways to accelerate regulatory assessment of innovative medicines in Latin America.
    Padua A; Partika L; Bonamici D; Rahal Cabello J; Kohiyama C; Spinardi P; Castro A; Rolim A; Souto F
    J Public Health Policy; 2020 Dec; 41(4):481-495. PubMed ID: 32879437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.
    Ncube BM; Dube A; Ward K
    J Pharm Policy Pract; 2021 Mar; 14(1):29. PubMed ID: 33685518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.
    Vaggelas A; Seimetz D
    Ther Innov Regul Sci; 2019 May; 53(3):364-373. PubMed ID: 29895180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.